• Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
Top Trading Strategy
No Result
View All Result
Home Breaking News

Google-parent Alphabet has set up a new lab that will use A.I. to try to discover new drugs

by
November 5, 2021
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Related Posts

The market’s worst first half in 50 years has all come down to one thing

Stocks trim losses, but the S&P 500 is on track for worst first half in decades

‘I wouldn’t be successful at my job without her’: My friend cleans, cooks and cares for my child. I pay her $50 a day. Am I taking advantage of her?

Housing shortage starts easing as listings surge in June

British artificial intelligence scientist and entrepreneur Demis Hassabis.

OLI SCARFF | AFP | Getty Images

Google parent company Alphabet has launched a new drug discovery company in the U.K. called Isomorphic Labs.

The company will build on research carried out by London artificial intelligence lab DeepMind, which Google acquired in 2014. While the firm was only officially announced on Thursday, it was incorporated in February, according to a filing with Companies House, the U.K. company registry.

Demis Hassabis, the CEO and co-founder of DeepMind, is also the founder and CEO of Isomorphic Labs. He will remain CEO of DeepMind.

In a blog post, Hassabis described Isomorphic Labs as a commercial venture with a mission to “reimagine the entire drug discovery process from the ground up.”

A spokesperson for Isomorphic Labs stressed that the company is separate from DeepMind and that it has its own dedicated resources. They stopped short, however, of saying how many staff or how much capital it has at its disposal.

“Where relevant, teams from both companies may collaborate, especially in the early days as Isomorphic Labs is hiring its team,” the spokesperson said.

Isomorphic Labs plans to use artificial intelligence software to create new drugs and medicines.

Identifying new drugs is a long, complex trial-and-error process that involves combining lots of different compounds in different ways. Several companies including London’s BenevolentAI and San Francisco’s Atomwise believe that AI can speed up the process.

“We believe that the foundational use of cutting edge computational and AI methods can help scientists take their work to the next level, and massively accelerate the drug discovery process,” wrote Hassabis, a former child chess prodigy with degrees in computer science and cognitive neuroscience from Cambridge and University College London, respectively.

“AI methods will increasingly be used not just for analyzing data, but to also build powerful predictive and generative models of complex biological phenomena,” he added.

Alphabet has several other companies working on health care including Verily, which is developing software for the health care sector, and Calico, which is working on ageing and extending the human life.

DeepMind has also worked on health care, and it used to have its own dedicated DeepMind Health division. However, this was absorbed by Google in 2018 after a controversial deal with Britain’s National Health Service.

Since then, DeepMind has pursued research in other areas of life science and it has made breakthroughs in a field known as protein folding. Last year, the company announced that it had developed an AI system that can accurately predict the structure that proteins will fold into in a matter of days, solving a 50-year-old “grand challenge.”

Next Post

Stocks making the biggest moves premarket: Pfizer, Canada Goose, Live Nation and more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

Popular Posts

Breaking News

The market’s worst first half in 50 years has all come down to one thing

by
June 30, 2022
0

Traders on the floor of the NYSE, June 29, 2022. Source: NYSE A multitude of factors conspired to generate the...

Read more

The market’s worst first half in 50 years has all come down to one thing

Stocks trim losses, but the S&P 500 is on track for worst first half in decades

‘I wouldn’t be successful at my job without her’: My friend cleans, cooks and cares for my child. I pay her $50 a day. Am I taking advantage of her?

Apple opens up third-party app payments in Korea, will still take 26% cut

Housing shortage starts easing as listings surge in June

These are analysts’ favorite Dow stocks for the second half of 2022

Load More

All rights reserved by www.toptradingstrategy.net

  • Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
  • Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting

© 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.